7 Amendments of Ivo BELET related to 2018/2775(RSP)
Amendment 2 #
Recital B
B. whereas D9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the most known cannabinoids identified in cannabis. THC constitutes the main psychoactive and addictive constituent of cannabis, whilst CBD does not have intoxicating or addictive properties;
Amendment 11 #
Recital E
E. whereas EU countries differ widely in their legislation with respect to cannabis for medicinal purposes, as well as allowed quantities of medicinal cannabis and maximum levels of THC and CBD concentrations; which can lead to difficulties for countries applying a more prudent approach;
Amendment 43 #
Paragraph 1 a (new)
1a. Emphasizes that all possible use of medical cannabis must be based on scientific research which proves the functioning of the product and which shows that the same positive effect cannot be achieved by using ordinary medicines that do not have addictive effects;
Amendment 61 #
Paragraph 7
7. Calls on Member States to encourage increased knowledge among medical professionals regarding the use of such cannabis-based medicine and consider allowing doctors to freely use their professional judgement to prescribe cannabis and cannabis-based medicines to patients with relevant conditions, and allow pharmacists to lawfully honour those prescriptionsprovide proper medical training regarding the use of such cannabis-based medicine; emphasizes that this training should be based on relevant scientific research; highlights the need for this training and access to literature for all medical staff - medical students, medical doctors and pharmacists;
Amendment 69 #
Paragraph 8 a (new)
8a. Calls on the Member States to reconsider their relevant legislation on the use of cannabis-based medicines when scientific research proves that the same positive effect cannot be achieved by using ordinary medicines that do not have addictive effects;
Amendment 72 #
Paragraph 9
9. Calls on Member States to secure sufficient availability of safe and controlled cannabis for medicinal purposes to cater for the actual needs; be it by local production in Member States or by imports complying with the national requirements for cannabis-based medicines;
Amendment 78 #
Paragraph 10
10. Underlines how a comprehensive and evidence based regulation of medical cannabis would translate in additional resources for public authorities, would limit the black market for medical cannabis consumption, would help control points of sale, would limit the access of this substance to minors and would give a legal and safe access to patients for its medicinal use - with particular precautions for young people and pregnant women;